Surgery Extends Lives of Women with Metastatic Breast Cancer, Study Says

Surgery Extends Lives of Women with Metastatic Breast Cancer, Study Says
Women with HER2-positive breast cancer that has spread to distant organs live longer if they have surgery to remove their primary tumor, according to research presented at the recent American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. The findings were featured on the poster, "The impact of primary tumor surgery on survival in HER2 positive stage IV breast cancer patients in the current era of targeted therapy," and presented by Ross Mudgway, a medical student at the University of California, Riverside School of Medicine. Between 20-30% of patients with stage 4 breast cancer (a stage in which cancer has already spread to other organs) are HER2-positive. HER2, or human epidermal growth factor receptor 2, is a protein that sends signals to stimulate cell growth and is normally associated with aggressive forms of breast cancer. According to Mudgway, the study's lead author, HER2-positive breast cancer was normally associated with poor clinical outcomes for patients. However, with the development of HER2-targeting therapies, such as Herceptin (trastuzumab) or Kadcycla (ado-trastuzumab emtansine), patients have seen their survival outcomes improve significantly. The recommended course of treatment for most patients with HER2-positive breast can
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.